

Brolucizumab for treating diabetic macular oedema

Information for the public

Published: 31 August 2022

www.nice.org.uk

Brolucizumab (Beovu) is available on the NHS as a possible treatment for visual impairment caused by diabetic macular oedema in adults. It's only available if, in the eye being treated, the central retina (area in the back of the eye) is above a certain thickness (400 micrometres or more) at the start of treatment.

If you are not eligible for brolucizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [Macular Society](#), 0300 3030 111
- [Diabetes UK](#), 0345 123 2399
- [Royal National Institute of Blind People \(RNIB\)](#), 0303 123 9999

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4738-6